Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
about
An Integrative Platform for Three-dimensional Quantitative Analysis of Spatially Heterogeneous Metastasis LandscapesMultimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapyToward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data.Sunitinib in metastatic renal cell carcinoma patients with brain metastases.Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases.Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.Innovative therapeutic strategies in the treatment of brain metastases.Targeted therapies in brain metastases.Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression.Therapy and prophylaxis of brain metastases.Brain metastases as preventive and therapeutic targets.Sorafenib for the management of advanced renal cell carcinoma.Revisiting the role of molecular targeted therapies in patients with brain metastases.Chemoprevention for brain metastases.Targeted therapies for renal cell carcinoma: review of adverse event management strategies.Sorafenib for the treatment of renal cancer.Treating patients with metastatic renal carcinoma: an escape from Phase III.Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma.Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS.Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis TherapyBrain metastases: an overview.Sorafenib: 10 years after the first pivotal trial.The future of targeted therapies for brain metastases.Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors.Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma.Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases.A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases.Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab
P2860
Q27322772-4FB9420D-B44C-4B14-AF0E-8BEF84711415Q28077050-4C346097-23D5-4B07-A27A-D5E62EB08084Q30557877-5225CFF8-3EEB-45B1-A463-C6D999EAE440Q33391978-5A2F876C-4EA1-4FB1-B717-4A8B52924EEEQ34206554-989BF4D3-F530-4135-AC8C-84042E99E807Q35738135-F34310E3-F985-4663-B520-C5ED243E5118Q35743315-1F702F5F-D307-4E50-9934-D79837DB04FFQ36242649-91981E7D-FDC1-455E-ABA0-DE44306E9F90Q36590195-E665AEFC-AB52-4994-87DA-90687D020A21Q37491460-507AEF6C-5E32-48A8-BC17-E3B4A311D050Q37559001-3EF801AB-8B34-416E-9008-946039AEC39FQ37809862-7CB8BC8C-754C-4E6C-88C8-113B7EAC0EF1Q37862581-E0A92A77-6936-4977-AE7B-5AD873EE783DQ37894667-1B15046E-F434-4E25-BADF-68315EB790DCQ37904792-6D96AF57-6987-4249-B7E8-A5724486DAD9Q37946748-99339EE8-24EC-46C1-A16C-9D3AE3758A90Q37974894-55B0058B-E08C-454B-A400-E78CC6873300Q37977494-907B78A3-14B1-4458-BBC8-C2026945865FQ38030592-A6F681B0-73FE-4A5A-BB2F-49DE08AA8891Q38048822-48AEB079-D0A3-4C7F-A329-AAA71AD9B88FQ38101607-A96FB8C5-7F92-431E-B137-7E117B0E0095Q38261946-2280AA10-072A-420D-93F8-BE1F7C773BF0Q38317417-29E03BF6-59C1-4160-B78A-F5D1874793E3Q38544841-1EE856CD-6783-4479-A05E-5B52F2E664F7Q38564085-B79B87BB-7D60-49B1-B5AD-8AC5C48C16E7Q38715328-B9E7C058-3183-4CA7-B862-D313185978FAQ40638741-1B20A9B6-4F88-4A0F-8410-E6F853242ED2Q45905781-553083E2-95E9-4ACF-835A-61BFC66E6B66Q48167222-12946BF3-57FC-4891-8BBD-275EBA93D5F4Q48189942-635C4DF0-5264-4F71-A129-936C28B39606Q54633298-B1B62FA2-00C9-419F-A4B4-DA04DFC1B2B1Q58545576-4557CFFA-9900-435D-9F6F-9D00125DDE54
P2860
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
@en
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
@nl
type
label
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
@en
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
@nl
prefLabel
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
@en
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
@nl
P2093
P356
P1433
P1476
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
@en
P2093
B Escudier
C Szczylik
J Zonierek
M Gross-Goupil
P304
P356
10.1093/ANNONC/MDP411
P577
2009-10-22T00:00:00Z